Tetanus – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 2 PAGES: 80

More Info
									                                Tetanus – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1896IDB
                                                                                             Publication Date: March 2012




Tetanus – Pipeline Review, H1 2012                                                          GMDHC1896IDB / Pub March 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                           Page(1)
Tetanus – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 6
    List of Figures ................................................................................................................................................................................ 7
Introduction......................................................................................................................................................................................... 8
    Global Markets Direct Report Coverage ........................................................................................................................................ 8
Tetanus Overview .............................................................................................................................................................................. 9
Therapeutics Development............................................................................................................................................................... 10
    An Overview of Pipeline Products for Tetanus ............................................................................................................................ 10
Tetanus Therapeutics under Development by Companies ............................................................................................................... 12
Tetanus Therapeutics under Investigation by Universities/Institutes ................................................................................................ 14
Late Stage Products ......................................................................................................................................................................... 15
    Comparative Analysis .................................................................................................................................................................. 15
Mid Clinical Stage Products.............................................................................................................................................................. 16
    Comparative Analysis .................................................................................................................................................................. 16
Early Clinical Stage Products ........................................................................................................................................................... 17
    Comparative Analysis .................................................................................................................................................................. 17
Pre-Clinical Stage Products.............................................................................................................................................................. 18
    Comparative Analysis .................................................................................................................................................................. 18
Tetanus Therapeutics – Products under Development by Companies............................................................................................. 19
Tetanus Therapeutics – Products under Investigation by Universities/Institutes .............................................................................. 20
Companies Involved in Tetanus Therapeutics Development............................................................................................................ 21
    Sanofi-Aventis ............................................................................................................................................................................. 21
    GlaxoSmithKline plc .................................................................................................................................................................... 22
    Merck & Co., Inc. ......................................................................................................................................................................... 23
    Takeda Pharmaceutical Company Limited .................................................................................................................................. 24
    Mitsubishi Tanabe Pharma Corporation ...................................................................................................................................... 25
    AVANIR Pharmaceuticals ............................................................................................................................................................ 26
    Green Cross Corporation ............................................................................................................................................................ 27
    LG Life Sciences, Ltd ................................................................................................................................................................. 28
    Panacea Biotec Limited ............................................................................................................................................................... 29
    iBio, Inc........................................................................................................................................................................................ 30
Tetanus – Therapeutics Assessment ............................................................................................................................................... 31
    Assessment by Monotherapy Products ....................................................................................................................................... 31
    Assessment by Combination Products ........................................................................................................................................ 32
    Assessment by Route of Administration ...................................................................................................................................... 33
    Assessment by Molecule Type .................................................................................................................................................... 35
Drug Profiles..................................................................................................................................................................................... 37
    Xenerex - Drug Profile ................................................................................................................................................................. 37
         Product Description................................................................................................................................................................. 37
         Mechanism of Action ............................................................................................................................................................... 37
         R&D Progress ......................................................................................................................................................................... 37
    GSK 792014 + Infanrix + Pediarix - Drug Profile ......................................................................................................................... 38



Tetanus – Pipeline Review, H1 2012                                                                                                               GMDHC1896IDB / Pub March 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                    Page(2)
Tetanus – Pipeline Review, H1 2012




        Product Description................................................................................................................................................................. 38
        Mechanism of Action ............................................................................................................................................................... 38
        R&D Progress ......................................................................................................................................................................... 38
    V501 + Menactra + Adacel - Drug Profile .................................................................................................................................... 40
        Product Description................................................................................................................................................................. 40
        Mechanism of Action ............................................................................................................................................................... 40
        R&D Progress ......................................................................................................................................................................... 40
    TdaP Vaccine - Drug Profile ........................................................................................................................................................ 42
        Product Description................................................................................................................................................................. 42
        Mechanism of Action ............................................................................................................................................................... 42
        R&D Progress ......................................................................................................................................................................... 42
    GSK2202083A + Prevenar 13 + Rotarix - Drug Profile................................................................................................................ 43
        Product Description................................................................................................................................................................. 43
        Mechanism of Action ............................................................................................................................................................... 43
        R&D Progress ......................................................................................................................................................................... 43
    Actacel - Drug Profile................................................................................................................................................................... 45
        Product Description................................................................................................................................................................. 45
        Mechanism of Action ............................................................................................................................................................... 45
        R&D Progress ......................................................................................................................................................................... 45
    DTaP-IPV-HB-PRP~T + Prevnar - Drug Profile ........................................................................................................................... 46
        Product Description................................................................................................................................................................. 46
        Mechanism of Action ............................................................................................................................................................... 46
        R&D Progress ......................................................................................................................................................................... 47
    Heptavalent Combination Vaccine - Drug Profile......................................................................................................................... 48
        Product Description................................................................................................................................................................. 48
        Mechanism of Action ............................................................................................................................................................... 48
        R&D Progress ......................................................................................................................................................................... 48
    Tdap - Drug Profile ...................................................................................................................................................................... 49
        Product Description................................................................................................................................................................. 49
        Mechanism of Action ............................................................................................................................................................... 49
        R&D Progress ......................................................................................................................................................................... 49
    GSK217744 Formulation B - Drug Profile .................................................................................................................................... 50
        Product Description................................................................................................................................................................. 50
        Mechanism of Action ............................................................................................................................................................... 50
        R&D Progress ......................................................................................................................................................................... 50
    GSK217744 Formulation A - Drug Profile .................................................................................................................................... 52
        Product Description................................................................................................................................................................. 52
        Mechanism of Action ............................................................................................................................................................... 52
        R&D Progress ......................................................................................................................................................................... 52
    Hexaxim - Drug Profile ................................................................................................................................................................ 54
        Product Description................................................................................................................................................................. 54
        Mechanism of Action ............................................................................................................................................................... 54
        R&D Progress ......................................................................................................................................................................... 54
    Quadracel - Drug Profile .............................................................................................................................................................. 55


Tetanus – Pipeline Review, H1 2012                                                                                                          GMDHC1896IDB / Pub March 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                              Page(3)
Tetanus – Pipeline Review, H1 2012




        Product Description................................................................................................................................................................. 55
        Mechanism of Action ............................................................................................................................................................... 55
        R&D Progress ......................................................................................................................................................................... 55
    DtwP-HB-Hib (Recon) Vaccine - Drug Profile .............................................................................................................................. 56
        Product Description................................................................................................................................................................. 56
        Mechanism of Action ............................................................................................................................................................... 56
        R&D Progress ......................................................................................................................................................................... 56
    Tetanus Toxin Monoclonal Antibody - Drug Profile...................................................................................................................... 57
        Product Description................................................................................................................................................................. 57
        Mechanism of Action ............................................................................................................................................................... 57
        R&D Progress ......................................................................................................................................................................... 57
    BK-4SP - Drug Profile .................................................................................................................................................................. 58
        Product Description.......................................................
								
To top